Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations
The RPMI 2650 and Calu-3 cell lines have been previously evaluated as models of the nasal and airway epithelial barrier, and they have demonstrated the potential to be used in drug permeation studies. However, limited data exist on the utilization of these two cell models for the assessment of nasal...
Saved in:
Main Authors: | Nadica Sibinovska (Author), Simon Žakelj (Author), Jurij Trontelj (Author), Katja Kristan (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Modified Cell-Penetrating Peptide Enhances Insulin and Oxytocin Delivery across an RPMI 2650 Nasal Epithelial Cell Barrier In Vitro
by: Sara Wong, et al.
Published: (2024) -
Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650
by: Simone Ladel, et al.
Published: (2019) -
In Vitro Ciliotoxicity and Cytotoxicity Testing of Repeated Chronic Exposure to Topical Nasal Formulations for Safety Studies
by: Larisa Tratnjek, et al.
Published: (2021) -
Investigation of the inhibitory effects of simvastatin in RPMI 2650: an in-vitro study / Jaapar K. H. ... [et al.]
by: Jaapar, K.H, et al.
Published: (2022) -
Puerarin transport across a Calu-3 cell monolayer – an in vitro model of nasal mucosa permeability and the influence of paeoniflorin and menthol
by: Zhang L, et al.
Published: (2016)